Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics (CARM)
OTHER OTC:CARM
CARM Stock Chart & Stats
$0.04
-$0.04(-7.53%)
At close: 4:00 PM EST
$0.04
-$0.04(-7.53%)
Day’s Range― - ―
52-Week Range$0.03 - $1.27
Previous CloseN/A
Volume72.54K
Average Volume (3M)2.25M
Market Cap
$1.47M
Enterprise Value$16.07M
Total Cash (Recent Filing)$2.00M
Total Debt (Recent Filing)$1.70M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Nov 06, 2025EPS Estimate
-0.12Last Dividend Ex-Date
Mar 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding41,788,097
10 Day Avg. Volume3,913,183
30 Day Avg. Volume2,245,153
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap10.95
Enterprise Value/Revenue1.49
Enterprise Value/Gross Profit1.65
Enterprise Value/Ebitda-0.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe mesothelin targeted autologous CAR monocyte program is expected to show evidence of clinical responses and clean safety, which should de-risk and validate the monocyte platform.
Strategic PartnershipsCarisma will focus on developing off-the-shelf products using its in vivo macrophage engineering platform, including those under the Moderna partnership.
Bears Say
Program DiscontinuationCarisma Therapeutics announced that it would be discontinuing development of its lead program, CT-0525.
Workforce ReductionAs part of the strategic restructuring, Carisma will reduce its workforce by 34%.
Carisma Therapeutics News
CARM FAQ
What was Carisma Therapeutics’s price range in the past 12 months?
Carisma Therapeutics lowest stock price was $0.03 and its highest was $1.27 in the past 12 months.
What is Carisma Therapeutics’s market cap?
Carisma Therapeutics’s market cap is $1.47M.
When is Carisma Therapeutics’s upcoming earnings report date?
Carisma Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 12 days.
How were Carisma Therapeutics’s earnings last quarter?
Carisma Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.14.
Is Carisma Therapeutics overvalued?
According to Wall Street analysts Carisma Therapeutics’s price is currently Overvalued.
Does Carisma Therapeutics pay dividends?
Carisma Therapeutics pays a Notavailable dividend of $0.361 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here
What is Carisma Therapeutics’s EPS estimate?
Carisma Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Carisma Therapeutics have?
Carisma Therapeutics has 41,788,097 shares outstanding.
What happened to Carisma Therapeutics’s price movement after its last earnings report?
Carisma Therapeutics reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Carisma Therapeutics?
Currently, no hedge funds are holding shares in CARM
Company Description
Carisma Therapeutics
Carisma Therapeutics (CARM) is a biopharmaceutical company focused on developing innovative cell-based therapies for the treatment of cancer and other serious diseases. The company specializes in its proprietary CAR-M (Chimeric Antigen Receptor Macrophage) technology, which harnesses the power of macrophages to target and destroy tumor cells. By leveraging its expertise in immunotherapy, Carisma aims to create breakthrough therapies that improve patient outcomes and transform the landscape of cancer treatment.
Technical Analysis
AIM ImmunoTech
―
GT Biopharma
―
Sensei Biotherapeutics
―
Bolt Biotherapeutics
―
CERo Therapeutics Holdings
―
Ownership Overview
1.16% Insiders
1.60% Mutual Funds
<0.01% Other Institutional Investors
97.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---